DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/334c12/competitive_analys) has announced the addition of the "Competitive Analysis of U.S. Pharmaceutical Industry, 2011" report to their offering.
This report is a detailed analysis of leading pharmaceutical companies in the U.S. pharmaceutical industry. Key players analysed in the report are - Pfizer, Merck, AstraZeneca, Novartis and Eli Lilly.
Comparative analysis of companies is done on the basis of their sales and profits and other financial information. Detailed ratio analysis compares these companies on the basis of their revenue growth, profitability, efficiency, financial strength and investment returns.
This report also presents a brief profile and SWOT analysis of these companies along with their financial analysis and ratio analysis vis-a-vis industry. Lastly, this report analyses the M&A activity in the U.S. Pharmaceutical Industry in recent years.
Key Report Takeaways: U.S. healthcare spending in 2010 was US$2.3 trillion or 16% of GDP, more than any other country in the world. United States is the largest pharmaceutical market globally, with 2010 sales of US$307 billion or 40% of global sales.
In 2010, U.S. pharmaceutical sales grew at 2. 3%; and since 2001 market has grown at a CAGR of 6. 6%. Pharmaceutical sales in the United States are expected to reach US$328 billion in 2011 and up to US$420 billion by 2015; growing at a CAGR of 6.4% between 2010 and 2015.
Highly competitive industry with top 5 companies accounting for leading the pack is Pfizer with a market share of 8.52% followed by Merck (6.11%), AstraZeneca (5.95%), Novartis (5.1%) and Eli Lilly (4.65%).
Merck, AstraZeneca and Eli Lilly had the best profit margins among the peer group while Pfizer and Eli Lilly had better financial condition and efficiency ratio. In terms of investment ratios, AstraZeneca and Eli Lilly are better placed than their peers.
In last 2 years, apart from Merck, all other companies ended the period with a positive growth in their share prices with Novartis leading the peer group with 17% increase in its share prices.
Key Topics Covered:
U.S. Healthcare Sector
Generic Drugs Market Assessment
Distribution and Supply Chain Analysis
Growth Drivers and Constraints
Government Policies and Regulations
Mergers & Acquisitions Assessment
For more information on this report visit http://www.researchandmarkets.com/research/334c12/competitive_analys.